Address: Osenny Bulvar 23, 121609, Moscow,Russia
Tel: +7 495 781 39 09
Over the past 27 years, PAREXEL has developed significant expertise to assist clients in the worldwide pharmaceutical, biotechnology and medical device industries with the development and launch of their products in order to bring safe and effective treatments to the global marketplace for the patients who need them. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees.
We are a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.
Every biopharmaceutical company needs strategic partners to meet the demands of today’s complex global marketplace – partners than can help you accelerate pharmaceutical product development… reduce overhead costs…expand into new markets to maximize product value…make better “Go/No-Go” decisions…mitigate risk…reduce regulatory delays…improve quality…or leverage advanced technology for greater operational efficiency.
For all of your biopharmaceutical services, PAREXEL is right where you need us, delivering proven solutions based on more than 25 years of global clinical and consulting experience. We have helped companies of all sizes overcome the challenges of biopharmaceutical development and bring their products to market for the benefit of patients around the world.
What does “right where you need us” mean for you?
-Biopharmaceutical services wherever you need them, across the Americas, Europe, the Middle East, Africa, and the Asia/Pacific region
-A full range of clinical services across every phase of development – from pre-clinical and Phase I trials through large Phase IV post-marketing studies and medical communications
-Scientific and medical expertise across all major therapeutic areas
-Advanced clinical and imaging technologies to support every aspect of biopharmaceutical development
-Integrated consulting expertise encompassing the complete development cycle, including strategic partnering and licensing; product pipeline optimization; strategic compliance; reimbursement and market access; and development of leading-edge products such as biologics, biosimilars, and therapeutic vaccines
Most important, “right where you need us” means that PAREXEL has the experience and flexibility to provide the right combination of biopharmaceutical services to fit your specific product development requirements – making us the right strategic partner to help you succeed in a difficult global environment.
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
